Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 triple fixed-dose combination for genotype 1 chronic hepatitis C with compensated cirrhosis
2013-002458-66Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of daclatasvir, asunaprevir and beclabuvir in hepatitis C virus infection (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: SVR12 in treatment-naive arms. Started Jun 2015; status: completed.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2013-002458-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002458-66.